WASHINGTON - In response to a bill that would require the Department of Health and Human Services to negotiate directly with the manufacturers of single-source drugs without therapeutic equivalents covered under Medicare Part D, the Biotechnology Industry Organization (BIO) this week issued concrete numbers demonstrating savings realized by seniors under the existing free-market framework. (BioWorld Today)